Table 2. Association between genetic polymorphisms and bleeding risk in patients treated with direct oral anticoagulants.

Genetic polymorphisms	Molecular Consequence	Grouped genotypes	Patients with bleeding (n=50)	Patients without bleeding (n=418)	*P* value
F2 rs5896 (C>T)	Missense	CC, CT	26 (52.0)	279 (67.4)	0.030
		TT	24 (48.0)	135 (32.6)	
F10 rs5960 (C>T)	Synonymous	CC	6 (12.2)	97 (23.4)	0.076
		CT, TT	43 (87.8)	318 (76.6)	
FGA rs2070011 (T>C)	5'-UTR	TT, TC	35 (70.0)	341 (81.8)	0.047
		CC	15 (30.0)	76 (18.2)	
FGA rs6050 (T>C)	Missense	TT	15 (30.0)	88 (21.1)	0.151
		TC, CC	35 (70.0)	329 (78.9)	
FGA rs2070022 (G>A)	3'-UTR	GG	34 (68.0)	318 (76.6)	0.179
		GA, AA	16 (32.0)	97 (23.4)	
FGB rs1800788 (C>T)	Upstream	CC	8 (16.0)	50 (12.1)	0.428
		CT, TT	42 (84.0)	364 (87.9)	
FGB rs4220 (G>A)	Intronic	GG	34 (68.0)	307 (73.6)	0.397
		GA, AA	16 (32.0)	110 (26.4)	
FGB rs4463047 (T>C)	Downstream	TT	15 (31.3)	90 (22.1)	0.152
		TC, CC	33 (68.8)	318 (77.9)	
FGG rs2066865 (G>A)	Downstream	GG	16 (32.0)	87 (20.9)	0.074
		GA, AA	34 (68.0)	329 (79.1)	
FGG rs1800792 (T>C)	Upstream	TT, TC	40 (80.0)	381 (91.6)	0.019
		CC	10 (20.0)	35 (8.4)	

UTR: untranslated region.